Trial Profile
A Single-center, Single-arm, Prospective Phase II Clinical Study of the Efficacy and Safety of AK105 Combined With Anlotinib in the Treatment of Persistent, Recurrent, and Metastatic Cervical Cancer
Status:
Not yet recruiting
Phase of Trial:
Phase II
Latest Information Update: 02 Dec 2021
Price :
$35
*
At a glance
- Drugs Catequentinib (Primary) ; Penpulimab (Primary)
- Indications Adenocarcinoma; Adenosquamous carcinoma; Cervical cancer; Squamous cell cancer
- Focus Therapeutic Use
- 01 Dec 2021 New trial record